Clinical Trial Search

Primary: Percentage That Had Increase in Classes of Guideline Directed Medical Therapy — 66.2; 13.1 percentage of patients

Primary: Percentage of Evaluable Patients With Stage 2 r-HAT Who Died by the End of Hospitalization, Considering Only Deaths Possibly Related to r-HAT or Fexinidazole — 0…

Primary: No. of Participants Taking up Breast Cancer Screening at Three Months- Intention to Treat — 2225; 2064; 2137 participants

Primary: Absolute Change in Dual Task Cost to Gait Speed From Baseline to Immediately Post Intervention — -2.29; -3.88; 0.06; -0.10 unitless — p=0.02

Primary: Severity of Dementia-related Behavioral Symptoms — 10.32; 9.93; 10.42 score on a scale

Primary: Penn State Worry Questionnaire - Measure of Symptom Change — 42.1; 55.8 score on a scale — p=<0.05

Primary: Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results — 9 Participants

Primary: Knee Society Score — 89.7; 91.8; 89.9; 83.2 score on a scale

Primary: The Score of Hypoglycemia Knowledge — 5.8; 4.8 score on a scale

Primary: Intervention Ordering Rate — 113; 60 Participants

Primary: Measurement of Total and Unbound Penicillin-V Concentration — 2.07; 2.8; 5.03; 3.62 mg/L

Primary: Percentage of Eligible Patients Who Are Randomized — 44 Participants

Primary: Safety Profile of SL-172154 — 3; 6; 4; 9 Participants

Primary: Inhibitory Control: Reaction Time — 10.79; 5.47; 4.11; -0.61 millisecond — p=> 0.05

Primary: Number of Participants With Radium-223 Dichloride-/Placebo-related Adverse Events (AEs) — 0; 1; 1; 0 Participants